In both validation cohorts, their model was able to identify the HER2 breast cancer subtype with an AUC of 0.89 and predict neoadjuvant chemotherapy response to HER2-targeted therapy (AUC of 0.80 and 0.69, respectively). The gene discussed is ERBB2; the disease is breast carcinoma.